APLIF (Appili Therapeutics) Tariff Resilience Score: 4/10 (As of Jun. 28, 2026)


What is Appili Therapeutics Tariff Resilience Score?

Appili Therapeutics APLIF Tariff Resilience Score is 4 as of Jun. 28, 2026. The stock has 4 warning signs investors should review. Among 1,376 Biotechnology companies, Appili Therapeutics ranks better than 52.33% on this metric.

Appili Therapeutics has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

Appili Therapeutics has Appili Therapeutics Inc is vulnerable due to its reliance on international pharmaceutical supply chains. Tariffs on raw materials and finished products could impact costs. The company is exploring alternative suppliers but has limited pricing power.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Appili Therapeutics might have Average Resilient.

Appili Therapeutics  (OTCPK:APLIF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Appili Therapeutics Tariff Resilience Score Related Terms

APLIF vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Appili Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Appili Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Appili Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Appili Therapeutics's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 4 mean?
Appili Therapeutics (APLIF) has a Tariff Resilience Score of 4 as of Jun. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Appili Therapeutics ranks #656 out of 1376 companies in the Biotechnology industry, placing it in the top 47.7%.
Is Appili Therapeutics' Tariff Resilience Score too high?
Appili Therapeutics' current Tariff Resilience Score is 4. The Biotechnology industry median Tariff Resilience Score is 4.00. Appili Therapeutics' value of 4 is 0% at this industry median. Based on the distribution chart, Appili Therapeutics ranks #656 out of 1376 companies in the Biotechnology industry, which is above the industry midpoint.
How does Appili Therapeutics' Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Appili Therapeutics ranks #656 out of 1376 companies for Tariff Resilience Score. This puts Appili Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Appili Therapeutics' value of 4 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,376 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Appili Therapeutics's current Tariff Resilience Score of 4 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Appili Therapeutics's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Appili Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Appili Therapeutics (APLIF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.01 — trading 43.5% below its estimated fair value. The current Tariff Resilience Score is 4 and 0% at the Biotechnology industry median of 4.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Appili Therapeutics (APLIF), the current Tariff Resilience Score is 4 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Appili Therapeutics Business Description

Other Exchanges APLI:Canada
Address 1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes programs namely ATI-1701, ATI-1801.